SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Stasi, R. Articles by Amadori, S. Search for Related Content PubMed PubMed Citation Articles by Stasi, R. Articles by Amadori, S. Related Collections Clinical Trials and Observations Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 August 2001, Vol. 98, No. 4, pp. 952-957 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura Roberto Stasi, Adalberto Pagano, Elisa Stipa, and Sergio Amadori From the Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy; and the Department of Hematology, University of Rome "Tor Vergata," S. Eugenio Hospital, Rome, Italy. The role of rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, in the treatment of patients with chronic idiopathic thrombocytopenic purpura (ITP) has not been determined. The effectiveness and side effects of this therapeutic modality were investigated in a cohort of 25 individuals with chronic ITP. All patients had ITP that had been resistant to between 2 and 5 different therapeutic regimens, including 8 patients who had already failed splenectomy. Patients were scheduled to receive intravenous rituximab at the dose of 375 mg/m2 once weekly for 4 weeks. Rituximab infusion-related side effects were observed in 18 patients, but were of modest intensity and did not require discontinuation of treatment. A complete response (platelet count greater than 100 × 109/L) was observed in 5 cases, a partial response (platelet count between 50 and 100 × 109/L) in 5 cases, and a minor response (platelet count below 50 × 109/L, with no need for continued treatment) in 3 cases, with an overall response rate of 52%. In 7 cases, responses were sustained (6 months or longer). In 2 patients with relapsed disease, repeat challenge with rituximab induced a new response. In patients with a complete or partial response, a significant rise in platelet concentrations was observed early during the course of treatment, usually 1 week after the first rituximab infusion. No clinical or laboratory parameter was found to predict treatment outcome, although there was a suggestion that women and younger patients have a better chance of response. In conclusion, rituximab therapy has a limited but valuable effect in patients with chronic ITP. In view of its mild toxicity and the lack of effective alternative treatments, its use in the setting of chronic refractory ITP is warranted. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura Roberto Stasi, Elisa Stipa, Vittorio Forte, Paola Meo, and Sergio Amadori Blood 2002 99: 3872-3873. [Full Text] [PDF] This article has been cited by other articles: J. B. Bussel, D. J. Kuter, V. Pullarkat, R. M. Lyons, M. Guo, and J. L. Nichol Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP Blood, March 5, 2009; 113(10): 2161 - 2171. [Abstract] [Full Text] [PDF] K. Kelly, M. Gleeson, and P. T. Murphy Slow responses to standard dose rituximab in immune thrombocytopenic purpura Haematologica, March 1, 2009; 94(3): 443 - 444. [Full Text] [PDF] F. Zaja and R. Fanin Slow responses to standard dose rituximab in immune thrombocytopenic purpura. Author reply Haematologica, March 1, 2009; 94(3): 444 - 445. [Full Text] [PDF] F. Zaja, M. L. Battista, M. T. Pirrotta, S. Palmieri, M. Montagna, N. Vianelli, L. Marin, M. Cavallin, M. Bocchia, M. Defina, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura Haematologica, June 1, 2008; 93(6): 930 - 933. [Abstract] [Full Text] [PDF] T Fukushima, L Dong, T Sakai, T Sawaki, M Miki, M Tanaka, Y Masaki, Y Hirose, M Kuwana, and H Umehara Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus Lupus, March 1, 2008; 17(3): 210 - 214. [Abstract] [PDF] M. Ruggeri, S. Fortuna, and F. Rodeghiero Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature Haematologica, January 1, 2008; 93(1): 98 - 103. [Abstract] [Full Text] [PDF] D. J. DiLillo, Y. Hamaguchi, Y. Ueda, K. Yang, J. Uchida, K. M. Haas, G. Kelsoe, and T. F. Tedder Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice J. Immunol., January 1, 2008; 180(1): 361 - 371. [Abstract] [Full Text] [PDF] S. Berentsen Rituximab for the treatment of autoimmune cytopenias Haematologica, December 1, 2007; 92(12): 1589 - 1596. [Full Text] [PDF] D. Provan, T. Butler, M. L. Evangelista, S. Amadori, A. C. Newland, and R. Stasi Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults Haematologica, December 1, 2007; 92(12): 1695 - 1698. [Abstract] [Full Text] [PDF] J. W. Semple Rituximab disciplines T cells, spares platelets Blood, October 15, 2007; 110(8): 2784 - 2785. [Full Text] [PDF] R. Stasi, G. Del Poeta, E. Stipa, M. L. Evangelista, M. M. Trawinska, N. Cooper, and S. Amadori Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura Blood, October 15, 2007; 110(8): 2924 - 2930. [Abstract] [Full Text] [PDF] W. R. Sperr, K. Lechner, and I. Pabinger Rituximab for the treatment of acquired antibodies to factor VIII Haematologica, January 1, 2007; 92(1): 66 - 71. [Abstract] [Full Text] [PDF] L. Chung, A. A. Funke, E. F. Chakravarty, J. P. Callen, and D. F. Fiorentino Successful use of rituximab for cutaneous vasculitis. Arch Dermatol, November 1, 2006; 142(11): 1407 - 1410. [Full Text] [PDF] R. Stasi, E. Stipa, G. Del Poeta, S. Amadori, A. C. Newland, and D. Provan Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab Rheumatology, November 1, 2006; 45(11): 1432 - 1436. [Abstract] [Full Text] [PDF] S. Z. Latifzadeh and V. Entezari Chronic Refractory Idiopathic Thrombocytopenic Purpura (ITP) and Anti-CD20 Monoclonal Antibody: A Case Report Clinical and Applied Thrombosis/Hemostasis, October 1, 2006; 12(4): 489 - 492. [Abstract] [PDF] M. Salvi, G. Vannucchi, I. Campi, S. Rossi, P. Bonara, F. Sbrozzi, C. Guastella, S. Avignone, G. Pirola, R. Ratiglia, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur. J. Endocrinol., April 1, 2006; 154(4): 511 - 517. [Abstract] [Full Text] [PDF] C. M. Bennett, Z. R. Rogers, D. D. Kinnamon, J. B. Bussel, D. H. Mahoney, T. C. Abshire, H. Sawaf, T. B. Moore, M. L. Loh, B. E. Glader, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura Blood, April 1, 2006; 107(7): 2639 - 2642. [Abstract] [Full Text] [PDF] A. L. Perrotta Re-treatment of Chronic Idiopathic Thrombocytopenic Purpura With Rituximab: Literature Review Clinical and Applied Thrombosis/Hemostasis, January 1, 2006; 12(1): 97 - 100. [Abstract] [PDF] G. Luzzatto, G. Cella, and F. Fabris Sustained Response to Anti-CD20 Monoclonal Antibody in Severe Acute Primary Immune Thrombocytopenic Purpura: Report of One Adult Case Clinical and Applied Thrombosis/Hemostasis, January 1, 2006; 12(1): 120 - 121. [PDF] D. S. Beardsley ITP in the 21st Century Hematology, January 1, 2006; 2006(1): 402 - 407. [Abstract] [Full Text] [PDF] E. R. Ahn, C. J. Bidot, V. Fontana, P. Dudkiewicz, W. Jy, L. Horstman, and Y. S. Ahn Rituximab Therapy Induces Long Lasting Clinical Remissions and Reduction of Anti-Platelet Glycoprotein Autoantibodies in Patients with Chronic Immune Thrombocytopenic Purpura (ITP). Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 4006 - 4006. [Abstract] K. Dunussi-Joannopoulos, G. E. Hancock, A. Kunz, M. Hegen, X. X. Zhou, B. J. Sheppard, J. Lamothe, E. Li, H.-L. Ma, P. R. Hamann, et al. B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model Blood, October 1, 2005; 106(7): 2235 - 2243. [Abstract] [Full Text] [PDF] D. B. Cines and J. B. Bussel How I treat idiopathic thrombocytopenic purpura (ITP) Blood, October 1, 2005; 106(7): 2244 - 2251. [Full Text] [PDF] S A Chambers and D Isenberg Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases Lupus, March 1, 2005; 14(3): 210 - 214. [Abstract] [PDF] M. Tokunaga, K. Fujii, K. Saito, S. Nakayamada, S. Tsujimura, M. Nawata, and Y. Tanaka Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab Rheumatology, February 1, 2005; 44(2): 176 - 182. [Abstract] [Full Text] [PDF] J. C. W. Edwards and G. Cambridge Prospects for B-cell-targeted therapy in autoimmune disease Rheumatology, February 1, 2005; 44(2): 151 - 156. [Full Text] [PDF] H Tahir and D A Isenberg Novel therapies in lupus nephritis Lupus, January 1, 2005; 14(1): 77 - 82. [Abstract] [PDF] J. Cabrera, F. J. Penalver, I. Millan, V. Jimenez-Yuste, M. Almagro, A. Alvarez-Larran, L. Rodriguez, and other 36 participants in the multicentric retrospe Mabthera (Rituximab) in the Treatment of 92 Patients with Refractory Immune Thrombocytopenic Purpura. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 2074 - 2074. [Abstract] R H Carter B cell signalling as therapeutic target Ann Rheum Dis, November 1, 2004; 63(suppl_2): ii65 - ii66. [Full Text] [PDF] H. Knecht, M. Baumberger, A. Tobon, and A. Steck Sustained remission of CIDP associated with Evans syndrome Neurology, August 24, 2004; 63(4): 730 - 732. [Abstract] [Full Text] [PDF] R. Stasi, M. Brunetti, E. Stipa, and S. Amadori Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia Blood, June 15, 2004; 103(12): 4424 - 4428. [Abstract] [Full Text] [PDF] C Gorman, M Leandro, and D Isenberg Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus? Lupus, May 1, 2004; 13(5): 312 - 316. [Abstract] [PDF] R J Looney, J Anolik, and I Sanz B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells Lupus, May 1, 2004; 13(5): 381 - 390. [Abstract] [PDF] R. Stasi and D. Provan Management of Immune Thrombocytopenic Purpura in Adults Mayo Clin. Proc., April 1, 2004; 79(4): 504 - 522. [Abstract] [PDF] M. Kuwana, S. Nomura, K. Fujimura, T. Nagasawa, Y. Muto, Y. Kurata, S. Tanaka, and Y. Ikeda Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura Blood, February 15, 2004; 103(4): 1229 - 1236. [Abstract] [Full Text] [PDF] S. K. Vesely, J. J. Perdue, M. A. Rizvi, D. R. Terrell, and J. N. George Management of Adult Patients with Persistent Idiopathic Thrombocytopenic Purpura Following Splenectomy: A Systematic Review Ann Intern Med, January 20, 2004; 140(2): 112 - 120. [Abstract] [Full Text] [PDF] A. Dupuy, M. Viguier, C. Bedane, F. Cordoliani, S. Blaise, F. Aucouturier, J.-M. Bonnetblanc, P. Morel, L. Dubertret, and H. Bachelez Treatment of Refractory Pemphigus Vulgaris With Rituximab (Anti-CD20 Monoclonal Antibody) Arch Dermatol, January 1, 2004; 140(1): 91 - 96. [Abstract] [Full Text] [PDF] R. Hassan, J. Williams-Gould, T. Watson, L. Pai-Scherf, and I. Pastan Pretreatment with Rituximab Does Not Inhibit the Human Immune Response against the Immunogenic Protein LMB-1 Clin. Cancer Res., January 1, 2004; 10(1): 16 - 18. [Abstract] [Full Text] [PDF] T. D. Shanafelt, H. L. Madueme, R. C. Wolf, and A. Tefferi Rituximab for Immune Cytopenia in Adults: Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome Mayo Clin. Proc., November 1, 2003; 78(11): 1340 - 1346. [Abstract] [PDF] T Shaw, J Quan, and M C Totoritis B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience Ann Rheum Dis, November 1, 2003; 62(90002): ii55 - 59. [Full Text] [PDF] K Saito, M Nawata, S Nakayamada, M Tokunaga, J Tsukada, and Y Tanaka Letter to the Editor Lupus, October 1, 2003; 12(10): 798 - 800. [PDF] D. Sansonno, V. De Re, G. Lauletta, F. A. Tucci, M. Boiocchi, and F. Dammacco Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20 Blood, May 15, 2003; 101(10): 3818 - 3826. [Abstract] [Full Text] [PDF] M. Zecca, B. Nobili, U. Ramenghi, S. Perrotta, G. Amendola, P. Rosito, M. Jankovic, P. Pierani, P. De Stefano, M. R. Bonora, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children Blood, May 15, 2003; 101(10): 3857 - 3861. [Abstract] [Full Text] [PDF] K.-G. Fischer, B. Deschler, M. Lubbert, A. Wiestner, B. B. Weksler, and G. P. Schechter Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses Blood, May 1, 2003; 101(9): 3753 - 3754. [Full Text] [PDF] A Pestronk, J Florence, T Miller, R Choksi, M T Al-Lozi, and T D Levine Treatment of IgM antibody associated polyneuropathies using rituximab J. Neurol. Neurosurg. Psychiatry, April 1, 2003; 74(4): 485 - 489. [Abstract] [Full Text] [PDF] J. Boye, T. Elter, and A. Engert An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab Ann. Onc., April 1, 2003; 14(4): 520 - 535. [Abstract] [Full Text] [PDF] X. Zheng, A. M. Pallera, L. T. Goodnough, J. E. Sadler, and M. A. Blinder Remission of Chronic Thrombotic Thrombocytopenic Purpura after Treatment with Cyclophosphamide and Rituximab Ann Intern Med, January 21, 2003; 138(2): 105 - 108. [Abstract] [Full Text] [PDF] T. G. DeLoughery Thrombocytopenia in Critical Care Patients J Intensive Care Med, November 1, 2002; 17(6): 267 - 282. [Abstract] [PDF] A. Wiestner, H. J. Cho, A. S. Asch, M. A. Michelis, J. A. Zeller, E. I. B. Peerschke, B. B. Weksler, and G. P. Schechter Rituximab in the treatment of acquired factor VIII inhibitors Blood, October 16, 2002; 100(9): 3426 - 3428. [Abstract] [Full Text] [PDF] R J Looney Treating human autoimmune disease by depleting B cells Ann Rheum Dis, October 1, 2002; 61(10): 863 - 866. [Full Text] [PDF] U. P. Hegde, W. H. Wilson, T. White, and B. D. Cheson Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia Blood, August 28, 2002; 100(6): 2260 - 2262. [Abstract] [Full Text] [PDF] M. Engelhardt, A. Jakob, B. Ruter, M. Trepel, F. Hirsch, and M. Lubbert Severe cold hemagglutinin disease (CHD) successfully treated with rituximab Blood, August 13, 2002; 100(5): 1922 - 1923. [Full Text] [PDF] R. Stasi, E. Stipa, V. Forte, P. Meo, and S. Amadori Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura Blood, May 15, 2002; 99(10): 3872 - 3873. [Full Text] [PDF] M. Morselli, M. Luppi, L. Potenza, L. Facchini, S. Tonelli, D. Dini, G. Leonardi, A. Donelli, F. Narni, and G. Torelli Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatment Blood, May 1, 2002; 99(9): 3478 - 3479. [Full Text] [PDF] D. B. Cines and V. S. Blanchette Immune Thrombocytopenic Purpura N. Engl. J. Med., March 28, 2002; 346(13): 995 - 1008. [Full Text] [PDF] G. Emilia, M. Morselli, M. Luppi, G. Longo, R. Marasca, G. Gandini, L. Ferrara, N. D'Apollo, L. Potenza, M. Bertesi, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura Blood, February 15, 2002; 99(4): 1482 - 1485. [Abstract] [Full Text] [PDF] J. P. Catlett and B. M. Alving Update in Hematology Ann Intern Med, January 15, 2002; 136(2): 136 - 143. [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020